 Leigh Perreault
Concepts (337)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prediabetic State | 24 | 2024 | 247 | 6.360 |
Why?
| | Diabetes Mellitus, Type 2 | 50 | 2024 | 2573 | 4.610 |
Why?
| | Insulin Resistance | 34 | 2025 | 1241 | 3.940 |
Why?
| | Obesity | 32 | 2026 | 3070 | 3.340 |
Why?
| | Hypoglycemic Agents | 23 | 2023 | 1388 | 2.830 |
Why?
| | Weight Loss | 18 | 2026 | 839 | 2.450 |
Why?
| | Blood Glucose | 31 | 2023 | 2326 | 2.350 |
Why?
| | Weight Reduction Programs | 4 | 2026 | 138 | 2.140 |
Why?
| | Muscle, Skeletal | 22 | 2025 | 1788 | 2.110 |
Why?
| | Cardiovascular Diseases | 15 | 2020 | 2172 | 1.890 |
Why?
| | Primary Health Care | 8 | 2026 | 1730 | 1.720 |
Why?
| | Insulin | 20 | 2024 | 2502 | 1.670 |
Why?
| | Sphingolipids | 7 | 2024 | 83 | 1.570 |
Why?
| | Diabetes Mellitus | 11 | 2023 | 1076 | 1.500 |
Why?
| | Triglycerides | 11 | 2024 | 517 | 1.480 |
Why?
| | Glucose Intolerance | 8 | 2020 | 142 | 1.360 |
Why?
| | Benzhydryl Compounds | 3 | 2017 | 81 | 1.360 |
Why?
| | Diabetic Angiopathies | 3 | 2017 | 262 | 1.340 |
Why?
| | Diglycerides | 6 | 2024 | 59 | 1.220 |
Why?
| | Diabetes Complications | 2 | 2019 | 223 | 1.040 |
Why?
| | Overweight | 7 | 2022 | 606 | 1.010 |
Why?
| | Glucosides | 2 | 2017 | 55 | 1.000 |
Why?
| | Glucagon-Like Peptide 1 | 3 | 2023 | 146 | 0.930 |
Why?
| | Life Style | 12 | 2020 | 481 | 0.930 |
Why?
| | Exercise | 12 | 2025 | 2183 | 0.880 |
Why?
| | Metformin | 13 | 2023 | 320 | 0.850 |
Why?
| | Receptors, Gastrointestinal Hormone | 1 | 2023 | 7 | 0.810 |
Why?
| | Glucose Tolerance Test | 15 | 2021 | 360 | 0.790 |
Why?
| | Adipose Tissue | 5 | 2025 | 643 | 0.790 |
Why?
| | Anti-Obesity Agents | 2 | 2024 | 67 | 0.780 |
Why?
| | Adult | 57 | 2025 | 40489 | 0.770 |
Why?
| | Humans | 99 | 2026 | 144667 | 0.760 |
Why?
| | Glucose Clamp Technique | 11 | 2024 | 199 | 0.760 |
Why?
| | Cannabidiol | 1 | 2025 | 139 | 0.750 |
Why?
| | Goals | 2 | 2021 | 184 | 0.730 |
Why?
| | Dronabinol | 1 | 2025 | 249 | 0.710 |
Why?
| | Middle Aged | 47 | 2025 | 35971 | 0.700 |
Why?
| | Nutrition Therapy | 1 | 2022 | 37 | 0.690 |
Why?
| | Marijuana Use | 1 | 2025 | 212 | 0.680 |
Why?
| | Male | 63 | 2026 | 72431 | 0.660 |
Why?
| | Body Mass Index | 13 | 2025 | 2419 | 0.660 |
Why?
| | Liver | 4 | 2014 | 1889 | 0.660 |
Why?
| | Female | 68 | 2026 | 78304 | 0.650 |
Why?
| | Health Equity | 1 | 2023 | 132 | 0.640 |
Why?
| | Primary Care Nursing | 1 | 2019 | 4 | 0.620 |
Why?
| | Hyperglycemia | 4 | 2014 | 374 | 0.610 |
Why?
| | Weight Gain | 5 | 2025 | 557 | 0.580 |
Why?
| | Lipid Metabolism | 5 | 2025 | 524 | 0.570 |
Why?
| | Peripheral Vascular Diseases | 1 | 2019 | 104 | 0.560 |
Why?
| | Insulin, Long-Acting | 1 | 2019 | 65 | 0.560 |
Why?
| | Obesity Management | 1 | 2018 | 8 | 0.560 |
Why?
| | Infant, Newborn, Diseases | 1 | 2019 | 113 | 0.550 |
Why?
| | Microvessels | 1 | 2019 | 98 | 0.540 |
Why?
| | Cannabis | 1 | 2025 | 509 | 0.540 |
Why?
| | Awareness | 1 | 2019 | 109 | 0.540 |
Why?
| | Fasting | 4 | 2020 | 275 | 0.520 |
Why?
| | Policy | 1 | 2018 | 147 | 0.510 |
Why?
| | Ceramides | 5 | 2024 | 117 | 0.510 |
Why?
| | Risk Management | 1 | 2017 | 83 | 0.500 |
Why?
| | Precision Medicine | 1 | 2021 | 454 | 0.500 |
Why?
| | Incretins | 2 | 2021 | 21 | 0.490 |
Why?
| | Risk Factors | 19 | 2023 | 10796 | 0.480 |
Why?
| | Rest | 2 | 2017 | 123 | 0.480 |
Why?
| | Choristoma | 1 | 2015 | 20 | 0.460 |
Why?
| | Sleep Deprivation | 5 | 2021 | 206 | 0.440 |
Why?
| | Insulin-Secreting Cells | 2 | 2010 | 390 | 0.430 |
Why?
| | Inflammation | 1 | 2025 | 2870 | 0.400 |
Why?
| | Sarcolemma | 3 | 2024 | 35 | 0.390 |
Why?
| | Glucose | 4 | 2023 | 1033 | 0.380 |
Why?
| | Phenols | 1 | 2013 | 107 | 0.370 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1056 | 0.360 |
Why?
| | Colorado | 5 | 2026 | 4558 | 0.360 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2022 | 1742 | 0.360 |
Why?
| | Lipids | 4 | 2024 | 706 | 0.360 |
Why?
| | Aged | 18 | 2025 | 25955 | 0.340 |
Why?
| | Physical Endurance | 5 | 2020 | 274 | 0.340 |
Why?
| | Fenofibrate | 1 | 2011 | 28 | 0.330 |
Why?
| | Athletes | 7 | 2024 | 421 | 0.320 |
Why?
| | Glucagon-Like Peptides | 2 | 2022 | 70 | 0.320 |
Why?
| | Hypolipidemic Agents | 1 | 2011 | 89 | 0.320 |
Why?
| | Phosphatidylcholines | 2 | 2024 | 130 | 0.310 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2010 | 46 | 0.310 |
Why?
| | Palmitates | 1 | 2009 | 21 | 0.310 |
Why?
| | Pyrazines | 1 | 2010 | 92 | 0.300 |
Why?
| | Cross-Sectional Studies | 9 | 2024 | 5870 | 0.300 |
Why?
| | Hospitalization | 1 | 2019 | 2446 | 0.290 |
Why?
| | Triazoles | 1 | 2010 | 184 | 0.290 |
Why?
| | Energy Metabolism | 4 | 2021 | 927 | 0.280 |
Why?
| | Young Adult | 13 | 2025 | 14122 | 0.270 |
Why?
| | Biomarkers | 8 | 2023 | 4261 | 0.270 |
Why?
| | Electronic Health Records | 2 | 2026 | 1176 | 0.260 |
Why?
| | Risk Reduction Behavior | 3 | 2023 | 215 | 0.260 |
Why?
| | Sleep | 4 | 2021 | 890 | 0.260 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2017 | 29 | 0.260 |
Why?
| | Diabetic Nephropathies | 2 | 2020 | 318 | 0.250 |
Why?
| | Sex Characteristics | 3 | 2021 | 776 | 0.250 |
Why?
| | Markov Chains | 2 | 2018 | 130 | 0.240 |
Why?
| | Absenteeism | 2 | 2018 | 52 | 0.240 |
Why?
| | Double-Blind Method | 5 | 2024 | 2033 | 0.240 |
Why?
| | Sex Factors | 5 | 2018 | 2104 | 0.240 |
Why?
| | Health Services | 2 | 2018 | 114 | 0.230 |
Why?
| | Adiponectin | 3 | 2018 | 240 | 0.230 |
Why?
| | Muscle Fibers, Skeletal | 3 | 2024 | 214 | 0.220 |
Why?
| | Remission Induction | 3 | 2019 | 309 | 0.220 |
Why?
| | Follow-Up Studies | 6 | 2021 | 5414 | 0.220 |
Why?
| | Pilot Projects | 2 | 2021 | 1886 | 0.210 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2022 | 657 | 0.210 |
Why?
| | Carnitine | 2 | 2024 | 90 | 0.210 |
Why?
| | Circadian Rhythm | 3 | 2019 | 510 | 0.200 |
Why?
| | Lipogenesis | 2 | 2017 | 62 | 0.200 |
Why?
| | Dietary Fats | 3 | 2020 | 308 | 0.200 |
Why?
| | Lipoprotein Lipase | 1 | 2004 | 56 | 0.200 |
Why?
| | Cross-Over Studies | 1 | 2026 | 605 | 0.200 |
Why?
| | Hyperinsulinism | 1 | 2024 | 114 | 0.190 |
Why?
| | Physical Exertion | 1 | 2004 | 205 | 0.190 |
Why?
| | Oxidation-Reduction | 4 | 2024 | 1078 | 0.190 |
Why?
| | Healthy Lifestyle | 1 | 2023 | 37 | 0.190 |
Why?
| | Computer Simulation | 2 | 2018 | 1021 | 0.180 |
Why?
| | Diet, Reducing | 3 | 2017 | 91 | 0.180 |
Why?
| | Socioeconomic Factors | 2 | 2018 | 1322 | 0.180 |
Why?
| | Energy Intake | 4 | 2021 | 501 | 0.180 |
Why?
| | Biopsy | 3 | 2018 | 1079 | 0.180 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1268 | 0.180 |
Why?
| | Cluster Analysis | 1 | 2023 | 516 | 0.170 |
Why?
| | Endpoint Determination | 2 | 2019 | 84 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2024 | 2019 | 0.170 |
Why?
| | Nephrology | 1 | 2022 | 60 | 0.170 |
Why?
| | Prevalence | 2 | 2019 | 2839 | 0.170 |
Why?
| | Glucose Transporter Type 4 | 1 | 2021 | 39 | 0.170 |
Why?
| | Cytosol | 2 | 2020 | 214 | 0.170 |
Why?
| | Body Weight | 4 | 2024 | 968 | 0.160 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 267 | 0.160 |
Why?
| | Risk Adjustment | 1 | 2020 | 85 | 0.160 |
Why?
| | Endocrinologists | 1 | 2020 | 12 | 0.150 |
Why?
| | New Zealand | 1 | 2019 | 54 | 0.150 |
Why?
| | Cytosine | 1 | 2019 | 49 | 0.150 |
Why?
| | Endoplasmic Reticulum | 2 | 2020 | 264 | 0.150 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2019 | 133 | 0.150 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2019 | 154 | 0.140 |
Why?
| | Fatty Liver | 1 | 2021 | 250 | 0.140 |
Why?
| | Liraglutide | 1 | 2019 | 32 | 0.140 |
Why?
| | Exercise Test | 3 | 2015 | 626 | 0.140 |
Why?
| | Models, Econometric | 1 | 2018 | 34 | 0.140 |
Why?
| | Retinal Diseases | 1 | 2019 | 101 | 0.140 |
Why?
| | Postprandial Period | 1 | 2019 | 114 | 0.140 |
Why?
| | Quinolizines | 1 | 1997 | 9 | 0.130 |
Why?
| | Adolescent | 8 | 2023 | 22409 | 0.130 |
Why?
| | Drug Combinations | 1 | 2019 | 393 | 0.130 |
Why?
| | United States | 9 | 2023 | 16018 | 0.130 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 244 | 0.130 |
Why?
| | Antiemetics | 1 | 1997 | 48 | 0.130 |
Why?
| | Nausea | 1 | 1997 | 112 | 0.130 |
Why?
| | Cytokines | 1 | 2025 | 2045 | 0.130 |
Why?
| | Cholesterol, HDL | 2 | 2015 | 199 | 0.130 |
Why?
| | Health Resources | 1 | 2018 | 130 | 0.130 |
Why?
| | Vomiting | 1 | 1997 | 131 | 0.120 |
Why?
| | Referral and Consultation | 1 | 2023 | 852 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2922 | 0.120 |
Why?
| | Hysterectomy | 1 | 1997 | 137 | 0.120 |
Why?
| | Odds Ratio | 1 | 2019 | 1076 | 0.120 |
Why?
| | Patient-Centered Care | 1 | 2021 | 545 | 0.120 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 330 | 0.120 |
Why?
| | Patient Participation | 1 | 2019 | 428 | 0.120 |
Why?
| | Blotting, Western | 2 | 2016 | 1161 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 944 | 0.120 |
Why?
| | Phosphatidylethanolamines | 1 | 2016 | 76 | 0.120 |
Why?
| | Phenotype | 1 | 2024 | 3147 | 0.120 |
Why?
| | Eating | 2 | 2021 | 388 | 0.110 |
Why?
| | Research Design | 2 | 2019 | 1129 | 0.110 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 565 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 638 | 0.110 |
Why?
| | Kidney Diseases | 1 | 2019 | 427 | 0.110 |
Why?
| | Treatment Outcome | 6 | 2021 | 11735 | 0.110 |
Why?
| | Exercise Therapy | 2 | 2017 | 475 | 0.110 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 221 | 0.110 |
Why?
| | Patient Compliance | 1 | 2019 | 587 | 0.110 |
Why?
| | Income | 1 | 2015 | 201 | 0.100 |
Why?
| | Sleep Apnea Syndromes | 1 | 2015 | 96 | 0.100 |
Why?
| | Somatostatin | 1 | 2014 | 53 | 0.100 |
Why?
| | Hypoglycemia | 1 | 2019 | 479 | 0.100 |
Why?
| | Logistic Models | 1 | 2019 | 2114 | 0.100 |
Why?
| | Smoking | 2 | 2012 | 1467 | 0.100 |
Why?
| | Pneumonia | 1 | 2019 | 629 | 0.100 |
Why?
| | Indoles | 1 | 1997 | 504 | 0.100 |
Why?
| | Employment | 1 | 2015 | 184 | 0.100 |
Why?
| | Fructose | 1 | 2014 | 131 | 0.100 |
Why?
| | Recovery of Function | 2 | 2015 | 715 | 0.100 |
Why?
| | Health Personnel | 1 | 2019 | 746 | 0.100 |
Why?
| | Consensus | 3 | 2020 | 475 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2014 | 114 | 0.100 |
Why?
| | Cost of Illness | 1 | 2015 | 322 | 0.090 |
Why?
| | C-Reactive Protein | 1 | 2015 | 420 | 0.090 |
Why?
| | Oxygen Consumption | 4 | 2016 | 717 | 0.090 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 54 | 0.090 |
Why?
| | Multicenter Studies as Topic | 1 | 2014 | 408 | 0.090 |
Why?
| | Models, Theoretical | 1 | 2016 | 578 | 0.090 |
Why?
| | Homeostasis | 1 | 2016 | 639 | 0.090 |
Why?
| | Qualitative Research | 1 | 2019 | 1668 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2019 | 8284 | 0.090 |
Why?
| | Adult Children | 1 | 2011 | 27 | 0.090 |
Why?
| | Placebos | 2 | 2009 | 193 | 0.080 |
Why?
| | Prospective Studies | 3 | 2019 | 7994 | 0.080 |
Why?
| | Diabetes, Gestational | 1 | 2015 | 303 | 0.080 |
Why?
| | Mitochondria | 1 | 2018 | 984 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1569 | 0.080 |
Why?
| | Adipocytes | 1 | 2012 | 223 | 0.080 |
Why?
| | Age Factors | 1 | 2018 | 3329 | 0.080 |
Why?
| | Health Behavior | 2 | 2023 | 786 | 0.080 |
Why?
| | Sitagliptin Phosphate | 1 | 2010 | 31 | 0.080 |
Why?
| | Family Health | 1 | 2011 | 191 | 0.080 |
Why?
| | Comorbidity | 1 | 2015 | 1652 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2019 | 1406 | 0.080 |
Why?
| | Metabolomics | 1 | 2015 | 724 | 0.080 |
Why?
| | Longevity | 1 | 2011 | 175 | 0.080 |
Why?
| | Mitochondria, Muscle | 2 | 2021 | 120 | 0.070 |
Why?
| | C-Peptide | 1 | 2010 | 190 | 0.070 |
Why?
| | Quality of Life | 3 | 2019 | 3183 | 0.070 |
Why?
| | Disease Progression | 3 | 2024 | 2847 | 0.070 |
Why?
| | Menopause | 1 | 2011 | 319 | 0.070 |
Why?
| | Leisure Activities | 1 | 2008 | 30 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1766 | 0.060 |
Why?
| | Delphi Technique | 2 | 2019 | 330 | 0.060 |
Why?
| | Body Composition | 1 | 2011 | 689 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2117 | 0.060 |
Why?
| | Risk Assessment | 3 | 2015 | 3729 | 0.060 |
Why?
| | Fibrinogen | 2 | 2018 | 181 | 0.060 |
Why?
| | Cohort Studies | 4 | 2021 | 5957 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2009 | 1537 | 0.060 |
Why?
| | Regression Analysis | 2 | 2019 | 998 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2012 | 3910 | 0.060 |
Why?
| | Postoperative Complications | 1 | 1997 | 2950 | 0.050 |
Why?
| | Mass Screening | 1 | 2013 | 1348 | 0.050 |
Why?
| | Aging | 1 | 2015 | 1938 | 0.050 |
Why?
| | Metabolic Clearance Rate | 1 | 2004 | 115 | 0.050 |
Why?
| | Health Expenditures | 1 | 1986 | 194 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2023 | 1766 | 0.050 |
Why?
| | Incidence | 3 | 2019 | 2892 | 0.050 |
Why?
| | Hormones | 1 | 2004 | 133 | 0.050 |
Why?
| | Prognosis | 2 | 2023 | 4312 | 0.050 |
Why?
| | Menstrual Cycle | 1 | 2003 | 140 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2019 | 17149 | 0.050 |
Why?
| | Depression | 1 | 2012 | 1561 | 0.050 |
Why?
| | Parents | 1 | 2011 | 1395 | 0.050 |
Why?
| | Gastrointestinal Diseases | 1 | 2024 | 217 | 0.050 |
Why?
| | Eligibility Determination | 1 | 2023 | 72 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5967 | 0.050 |
Why?
| | Alcohol Drinking | 1 | 2009 | 827 | 0.050 |
Why?
| | Lactic Acid | 1 | 2003 | 303 | 0.040 |
Why?
| | Wakefulness | 2 | 2015 | 170 | 0.040 |
Why?
| | Animals | 3 | 2024 | 37948 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1322 | 0.040 |
Why?
| | Acute Disease | 1 | 2024 | 1029 | 0.040 |
Why?
| | Subcellular Fractions | 1 | 2021 | 73 | 0.040 |
Why?
| | Citric Acid Cycle | 1 | 2021 | 59 | 0.040 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2020 | 50 | 0.040 |
Why?
| | Injections, Subcutaneous | 1 | 2021 | 168 | 0.040 |
Why?
| | Kinetics | 1 | 2004 | 1602 | 0.040 |
Why?
| | Motor Activity | 2 | 2015 | 723 | 0.040 |
Why?
| | Protective Agents | 1 | 2020 | 42 | 0.040 |
Why?
| | Education | 1 | 2020 | 105 | 0.040 |
Why?
| | Stearoyl-CoA Desaturase | 2 | 2010 | 66 | 0.040 |
Why?
| | Proprotein Convertase 9 | 1 | 2020 | 87 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2013 | 1301 | 0.040 |
Why?
| | Poisson Distribution | 1 | 2019 | 78 | 0.040 |
Why?
| | Stakeholder Participation | 1 | 2019 | 83 | 0.040 |
Why?
| | E-Selectin | 1 | 2018 | 61 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 7140 | 0.040 |
Why?
| | Subcutaneous Fat | 1 | 2019 | 79 | 0.030 |
Why?
| | Pregnancy | 2 | 2015 | 7122 | 0.030 |
Why?
| | Probability | 1 | 2019 | 309 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2018 | 129 | 0.030 |
Why?
| | Chemokine CCL2 | 1 | 2018 | 112 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2019 | 172 | 0.030 |
Why?
| | Intra-Abdominal Fat | 1 | 2019 | 100 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2020 | 592 | 0.030 |
Why?
| | Research | 1 | 2020 | 431 | 0.030 |
Why?
| | Leptin | 1 | 2018 | 247 | 0.030 |
Why?
| | Diet | 3 | 2012 | 1270 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2017 | 3603 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 418 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 442 | 0.030 |
Why?
| | Adaptation, Physiological | 2 | 2010 | 567 | 0.030 |
Why?
| | Metabolome | 1 | 2019 | 385 | 0.030 |
Why?
| | Rats | 1 | 2024 | 5570 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 96 | 0.030 |
Why?
| | Diet, Fat-Restricted | 1 | 2015 | 79 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2013 | 2942 | 0.030 |
Why?
| | Melatonin | 1 | 2015 | 163 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2018 | 770 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1495 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2020 | 699 | 0.030 |
Why?
| | Calorimetry | 1 | 2013 | 69 | 0.020 |
Why?
| | Fatty Acids | 1 | 2016 | 454 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2012 | 55 | 0.020 |
Why?
| | Risk | 1 | 2015 | 911 | 0.020 |
Why?
| | Glycerol | 1 | 2012 | 90 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1844 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2015 | 308 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2010 | 2815 | 0.020 |
Why?
| | Calorimetry, Indirect | 1 | 2010 | 72 | 0.020 |
Why?
| | Antidepressive Agents | 1 | 2012 | 248 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 985 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2010 | 41 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 6041 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 334 | 0.020 |
Why?
| | Retinoid X Receptor gamma | 1 | 2009 | 4 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2591 | 0.020 |
Why?
| | PPAR alpha | 1 | 2009 | 54 | 0.020 |
Why?
| | Polysomnography | 1 | 2010 | 236 | 0.020 |
Why?
| | Women's Health | 1 | 2011 | 307 | 0.020 |
Why?
| | Bicycling | 1 | 2010 | 116 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 452 | 0.020 |
Why?
| | Coronary Disease | 1 | 2011 | 381 | 0.020 |
Why?
| | Phospholipids | 1 | 2010 | 214 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1704 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 794 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 973 | 0.020 |
Why?
| | Adiposity | 1 | 2012 | 529 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2350 | 0.020 |
Why?
| | Mice | 1 | 2024 | 18261 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2011 | 771 | 0.010 |
Why?
| | Genotype | 1 | 2011 | 1847 | 0.010 |
Why?
| | Infant Care | 1 | 1986 | 44 | 0.010 |
Why?
| | Infertility | 1 | 1986 | 55 | 0.010 |
Why?
| | Health Promotion | 1 | 2011 | 771 | 0.010 |
Why?
| | Delivery, Obstetric | 1 | 1986 | 161 | 0.010 |
Why?
| | Maternal Health Services | 1 | 1986 | 102 | 0.010 |
Why?
| | Anaerobic Threshold | 1 | 2003 | 25 | 0.010 |
Why?
| | Follicular Phase | 1 | 2003 | 38 | 0.010 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2003 | 84 | 0.010 |
Why?
| | Luteal Phase | 1 | 2003 | 46 | 0.010 |
Why?
| | Contraception | 1 | 1986 | 170 | 0.010 |
Why?
| | Catecholamines | 1 | 2003 | 87 | 0.010 |
Why?
| | Abortion, Induced | 1 | 1986 | 110 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2137 | 0.010 |
Why?
| | Heart Rate | 1 | 2003 | 853 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1986 | 6399 | 0.010 |
Why?
|
|
Perreault's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|